Proton pump inhibitors in children: A review

Digestive and Liver Disease

Volumn 35, Issue 10, 2003, Pages 738-746

  Marchetti, F ^a   Gerarduzzi, T ^a   Ventura, A ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Esophagitis; Gastro esophageal reflux disorders; Helicobacter pylori eradication; Pharmacological properties; Proton pump inhibitors

Indexed keywords

AMOXICILLIN; AMPICILLIN; BENZODIAZEPINE DERIVATIVE; CLARITHROMYCIN; CORTICOSTEROID; CYANOCOBALAMIN; DIGOXIN; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; KETOCONAZOLE; LANSOPRAZOLE; METHOTREXATE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANAPHYLAXIS; BARRETT ESOPHAGUS; CHILD; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA; INTERSTITIAL NEPHRITIS; LIVER DYSFUNCTION; MEDICAL INFORMATION SYSTEM; MULTIPLE ORGAN FAILURE; NAUSEA; OPTIC NERVE DISEASE; OPTIMAL DRUG DOSE; PANCREATITIS; REVIEW; STOMACH DISEASE; STOMACH PH; STOMACH POLYP; STOMACH SECRETION; STOMACH ULCER; TOXIC EPIDERMAL NECROLYSIS;

EID: 9644294965     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00420-1     Document Type: Review

References (66)

1. AAVV Progetto ARNO. Osservatorio sulla prescrizione farmaceutica pediatrica. Rapporto 2000. CINECA, 2002.
2. Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr 2002;91:339-47.
3. Buck ML. Using proton pump inhibitors in children. Pediatr Pharmacother 1999;4.
4. Katelaris PH. New drugs, old drugs: proton pump inhibitors. Med J Aust 1998;169:208-11.
5. Israel DM, Hassal E. Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998;27:568-79.
6. Langtry HD, Wilde MI. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997;54:473-500.
7. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001;61:1801-33.
8. Proton pump inhibitors. In: Olin BR, editor. Drug facts and comparisons. St. Louis: Facts and Comparisons, Inc. 1999:305k-r.
9. Tran A, Rey E, Pons G, Pariente-Khayat A, D'Athis P, Sallerin V, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002;71:359-67.
10. Scaillon M, Cadranel S. Safety data required for proton-pump inhibitor use in children. J Pediatr Gastroenterol Nutr 2002;35:113-8.
11. Zimmermann AE, Walters JK, Katona BG, Souney PE, Levine D. A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther 2001;23:660-79.
12. Cucchiara S, Minella R, Iervolino C, Franco MT, Campanozzi A, Franceschi M, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993;69:655-9.
13. Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123:148-54.
14. Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995;149:267-71.
15. Kato S, Ebina K, Fujii K, Chiba H, Nakagawa H. Effect on omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity. J Pediatr 1996;128:415-21.
16. De Giacomo C, Bawa P, Franceschi M, Luinetti O, Fiocca R. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997;24:528-32.
17. Hassall E, Israel D, Shepherd R, Radke M, Dalvag A, Skold B, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 2000;137:800-7.
18. Alliet P, Raes M, Bruneel E, Gillis P. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr 1998;132:352-4.
19. Bohmer CJ, Niezen-de Boer RC, Klinkenberg-Knol EC, Meuwissen SG. Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 1998;152:1113-8.
20. Varughese LA, Mazur LJ. Is Omeprazole helpful in the management of children with reflux oesophagitis? Arch Dis Child 2002;87:78-80.
21. Franco MT, Salvia G, Terrin G, Spadaro R, De Rosa I, Iula VD, et al. Lansoprazole in the treatment of gastro-oesophageal reflux in childhood. Dig Liver Dis 2000;32:660-6.
22. Faure C, Michaud L, Saghaghi EK, Popon M, Laurence M, Mougenot JF, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1397-402.
23. Kumar Y, Sarvananthan R. Gastro-oesophageal reflux in children. Clinical evidence. London: BMJ Publ Group; 2002.
24. Katzka D. Gastro-esophageal reflux disease. In: Godlee F, editor, Clinical evidence, London: BMJ Publ Group; 2000, pp. 225-35.
25. Van Pinxeteren B, Numans ME, Bonis PA, Lau J. Short term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease, The Cochrane Library, Vol. Issue 3. Oxford: Update Software Ltd; 2002.
26. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
27. Manes G, Mosca S, De Nucci C, Lombardi G, Lioniello M, Balzano A. High prevalence of reflux symptoms in duodenal ulcer patients who develop gastro-oesophageal reflux disease after curing Helicobacter pylori infection. Dig Liver Dis 2001;33:665-70.
28. Schwizer W, Thumshirn M, Dent J, Guldenschuh I, Menne D, Cathomas G, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357:1738-42.
29. Harris A, Misiewicz JJ. Management of Helicobacter pylori infection. Br Med J 2001;323:1047-50.
30. Chong SK. Gastrointestinal problems in the handicapped child. Curr Opin Pediatr 2001;13:441-6.
31. Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32(Suppl 2):S1-31.
32. Bazzoli F, Bianchi Porro G, Macani G, Molteni M, Pazzato P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis 2002;34:70-83.
33. Behrens R, Lang T, Keller KM, Bindl L, Becker M, Rodeck B, et al. Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. Arch Dis Child 1999;81:68-70.
34. Gottrand F, Kalach N, Spyckerelle C, Guimber D, Mougenot JF, Tounian P, et al. Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: a prospective randomised double-blind trial. J Pediatr 2001;139:664-8.
35. Shcherbakov PL, Filin VA, Volkov IA, Tatarinov PA, Belousov YB. A randomized comparison of triple therapy Helicobacter pylori eradication regimens in children with peptic ulcers. J Int Med Res 2001;29:147-53.
36. Kato S, Takeyama J, Ebina K, Naganuma H. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. Pediatrics 1997;100:e3.
37. Dohil R, Israel DM, Hassall E. Effective 2-wk therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1997;92:244-7.
38. Moshkowitz M, Reif S, Brill S, Ringel Y, Arber N, Halpern Z, et al. One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. Pediatrics 1998;102:e14.
39. Casswall TH, Alfven G, Drapinski M, Bergstrom M, Dahlstrom KA. One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylon infection. J Pediatr Gastroenterol Nutr 1998;27:415-8.
40. Kato S, Ritsuno H, Ohnuma K, Iinuma K, Sugiyama T, Asaka M. Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. Helicobacter 1998;3:278-82.
41. Shashidhar H, Peters J, Lin CH, Rabah R, Thomas R, Tolia V. A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylon infection. J Pediatr Gastroenterol Nutr 2000;30:276-82.
42. Valve M, Vergara M, Gisbert JP, Calvet X. Single versus double dose of a proton pump inhibitor in the triple therapy for Helicobacter pylon eradication: a meta-analysis. Aliment Pharmacol Ther 2002;16:1149-56.
43. Jones NL, Sherman PM. Approaching Helicobacter pylon infection in children: level I evidence at last and word of caution. J Pediatr 2001;139:622-3.
44. Gold BD, Colletti RB, Abbott M, Czinn SJ, Elitsur Y, Hassall E, et al. Helicobacter pylon infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7.
45. Drumm B, Koletzeko S, Oderda G. Helicobacter pylon infection in children: a consensus statement. J Pediatr Gastroenterol Nutr 2000;30:207-13.
46. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of non steroidal anti-inflammatory drugs-induced gastrointestinal mucosal injury. A meta-analysis of randomised controlled clinical trial. Arch Intern Med 1996;156:2321-32.
47. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. New Engl J Med 1998;338:719-26.
48. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. New Engl J Med 1998;338:727-34.
49. Rostom J, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Cochrane Database of Systematic Reviews. Issue 3, 2002.
50. Conn HO, Poynard T. Corticosteroids use and peptic ulcer disease: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-32.
51. Weil J, Langman MJ, Wainwright P, Lawson DH, Rawlins M, Logan RF, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31.
52. De Giacomo C, Fiocca R, Villani L, Licardi G, Scotta MS, Solcia E. Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant. J Pediatr 1990;117:989-93.
53. Kaufman SS, Lyden ER, Brown CR, Davis CK, Andersen DA, Olsen KM, et al. Omeprazole therapy in pediatric patients after liver and intestinal transplantation. J Pediatr Gastroenterol Nutr 2002;34:194-8.
54. Logan AJ, Morris-Stiff GJ, Bowrey DJ, Jurewicz WA. Upper gastrointestinal complications after renal transplantation: a 3 year sequential study. Clin Transpl 2002;16:163-7.
55. Nishina K, Mikawa K, Maekawa N, Tamada M, Obara H. Omeprazole reduces preoperative gastric fluid acidity and volume in children. Can Anaesth 1994;41:925-9.
56. Mikawa K, Nishina K, Maekawa N, Asano M, Obara H. Lansoprazole reduces preoperative gastric fluid acidity and volume in children. Can J Anaesth 1995;42:467-72.
57. Francisco MP, Wagner MH, Sherman JM, Theriaque D, Bowser E, Novak DA. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35:79-83.
58. Faure C, Michaud L, Shaghaghi EK, Popon M, Turck D, Navarro J, et al. Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. J Pediatr Gastroenterol Nutr 2001;33:144-8.
59. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of lansoprazole: the US clinical trial experience. Drug Saf 1999;20:195-205.
60. Romero-Gomez M, Otero MA, Suarez-Garcia E, Garcia Diaz E, Fobelo MJ, Castro-Fernandez M. Acute hepatitis related to omeprazole. Am J Gastroenterol 1999;94:1119-20.
61. Pashankar DS, Israel DM, Jevon GP, Buchan AM. Effect of long-term omeprazole treatment on antral G and D cells in children. J Pediatr Gastroenterol Nutr 2001;33:537-42.
62. Husebye E, Skar V, Hoverstad T, Iversen T, Melby K. Abnormal intestinal motor pattern explain enteric colonization with Gram-negative bacilli in late radiation enteropathy. Gastroenterology 1995;109:1078-89.
63. Cothran DS, Borowitz SM, Sutphen JL, Dudley SM, Donowitz LG. Alteration of normal gastric flora in neonates receiving ranitidine. J Perinatol 1997;17:383-8.
64. Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998;44:290-1.
65. Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-30.
66. ter Heide H, Hendriks HJ, Heijmans H, Menheere PP, Spaapen LJ, Bakker JA, et al. Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B12 deficiency? J Pediatr Gastroenterol Nutr 2001;33:342-5.